Citations

Clear

9383 citation(s) found for "Thomas, PS".

Avoiding Unintended Toxicity
Golde, Todd E. , Kukar, Thomas

Mayo Clinic

Science | April 30, 2009 | Volume: 324 | Issue: 5927 | Pages: 603-604

10.1126/science.1174267 | PMID 19407192 Get It

Drugs that inhibit a distinct form of γ-secretase may be useful in treating Alzheimer's disease without causing harmful side effects.
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma
Roccaro, Aldo M. , Sacco, Antonio , Thompson, Brian , Leleu, Xavier , Azab, Feda, Runnels, Judith, Jia, Xiaoying , Ngo, Hai T., Melhem, Molly, Lin, Charles P. , Rollins, Barrett J. , Azab, Abdel Kareem , Ribatti, Doménico , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M. , Roccaro, Aldo M

Mayo Clinic

Blood | April 29, 2009 | Volume: 113 | Issue: 26 | Pages: 6669-6680

10.1182/blood-2009-01-198408 | PMID 19401561 Get It

Abstract Detailed genomic studies have shown that cytogenetic abnormalities contribute to multiple myeloma (MM) pathogenesis and disease progression. Nevertheless, little is known about the characteristics of MM at the epigenetic level and specifically how microRNAs regulate MM progression in the context of the bone marrow milieu. Therefore, we performed microRNA expression profiling of bone marrow derived CD138+ MM cells versus their normal cellular counterparts and validated data by qRT-PCR. We identified a MM-specific microRNA signature characterized by down-expression of microRNA-15a/-16 and overexpression of microRNA-222/-221/-382/-181a/-181b (P < .01). We investigated the functional role of microRNA-15a and -16 and showed that they regulate proliferation and growth of MM cells in vitro and in vivo by inhibiting AKT serine/threonine-protein-kinase (AKT3), ribosomal-protein-S6, MAP-kinases, and NF-κB-activator MAP3KIP3. Moreover, miRNA-15a and -16 exerted their anti-MM activity even in the context of the bone marrow milieu in vitro and in vivo. These data indicate that microRNAs play a pivotal role in the biology of MM and represent important targets for novel therapies in MM.
Development of an International Questionnaire to Measure Use of Complementary and Alternative Medicine (I-CAM-Q)
Quandt, Sara A. , Verhoef, Marja J., Arcury, Thomas A. , Lewith, George , Steinsbekk, Aslak , Kristoffersen, Agnete E. , Wahner‐Roedler, Dietlind L. , Fønnebø, Vinjar

Mayo Clinic

The Journal of Alternative and Complementary Medicine | April 23, 2009 | Volume: 15 | Issue: 4 | Pages: 331-339

10.1089/acm.2008.0521 | PMID 19388855 Get It

Utility of Topiramate for the Treatment of Patients with Chronic Migraine in the Presence or Absence of Acute Medication Overuse
Diener, HC, Dodick, DW, Goadsby, Peter J. , Bigal, ME, Bussone, G. , Silberstein, SD, Mathew, N. T., Ascher, Simon B., Morein, Jacqueline, Hulihan, JF, Biondi, DM, Greenberg, SJ, Ascher, Simon B. , Hulihan, Joseph, Goadsby, Peter J

Mayo Clinic

Cephalalgia | April 23, 2009 | Volume: 29 | Issue: 10 | Pages: 1021-1027

10.1111/j.1468-2982.2009.01859.x | PMID 19735529 Get It

Chronic migraine has been linked to the excessive use of acute headache medications. Medication overuse (MO) is commonly considered the most significant risk factor for the progression of migraine from an episodic to a chronic condition. Managing MO is a challenge. Discontinuation of the acute medication can result in withdrawal headache, nausea, vomiting and sleep disturbances. This review summarizes the results from two similarly designed, randomized, placebo- controlled, multicentre studies of chronic migraine conducted in the USA and European Union. Both studies demonstrate the efficacy and safety of the migraine preventive medication, topiramate, for the treatment of chronic migraine in patient populations both with and without MO. These studies may have important implications for the future of chronic migraine management, suggesting that detoxification prior to initiating prophylactic therapy may not be required in all patients if MO is present.
Stability of fentanyl 5 μg/mL diluted with 0.9% sodium chloride injection and stored in polypropylene syringes
McCluskey, Susan V, Graner, Kevin, Kemp, Jesse, Aloumanis, Vasileios, Ben, Michel, Kupiec, Thomas C, Vu, Nicole

Mayo Clinic

American Journal of Health-System Pharmacy | April 22, 2009 | Volume: 66 | Issue: 9 | Pages: 860-863

10.2146/ajhp080255 | PMID 19386950 Get It

Genetic Variation in B-Cell–Activating Factor Is Associated with an Increased Risk of Developing B-Cell Non–Hodgkin Lymphoma
Novak, Anne J. , Fredericksen, Zachary S., Wang, Alice H., Manske, Michelle M., Ziesmer, Steven C., Liebow, Mark , Macon, William R. , Dillon, Stacey R. , Cerhan, James R. , Ansell, Stephen M. , Slager, Susan L. , Manske, Michelle K. , Witzig, Thomas E. , Cerhan, James R

Mayo Clinic

Cancer Research | April 22, 2009 | Volume: 69 | Issue: 10 | Pages: 4217-4224

10.1158/0008-5472.can-08-4915 | PMID 19383901 Get It

Abstract Elevated B-cell–activating factor (BAFF; TNFSF13B) levels have been found in patients with B-cell malignancies and autoimmune diseases, suggesting that it may play a pathogenic role. We previously found that a single nucleotide polymorphism (SNP) in the TNFSF13B promoter resulted in increased transcription, suggesting that genetic variation in TNFSF13B may influence its expression. We therefore wanted to determine if genetic variation in TNFSF13B is associated with high BAFF levels and non–Hogkin lymphoma (NHL) risk. We genotyped 9 tagSNPs within TNFSF13B in a clinic-based study of 441 NHL cases and 475 matched controls and evaluated the association of individual SNPs with risk of NHL; 3 tagSNPs were significant (P &lt; 0.05). When categorized into low-, moderate-, and high-risk groups based on risk alleles, we found the permutation-corrected odds ratio for the trend to be 1.43 (P = 0.0019) for risk of B-cell NHL, 1.69 (P = 0.0093) for diffuse large B-cell lymphoma, 1.43 (P = 0.029) for follicular lymphoma, and 1.06 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma. The mean serum BAFF level in those who carried the low-risk alleles was 2 ng/mL compared with 4.3 ng/mL in those with the high-risk alleles (P = 0.02). Taken together, our data suggest that genetic variation in the TNFSF13B gene is significantly associated with NHL risk and elevated serum BAFF levels. [Cancer Res 2009;69(10):4217–24]
IL-23 Drives Pathogenic IL-17-Producing CD8+ T Cells
Ćirić, Bogoljub , Behi, Mohamed El , Cabrera, Rosalyn, Zhang, Guang‐Xian , Rostami, Abdolmohamad

Mayo Clinic

The Journal of Immunology | April 21, 2009 | Volume: 182 | Issue: 9 | Pages: 5296-5305

10.4049/jimmunol.0900036 | PMID 19380776 Get It

Abstract IL-17-producing CD8+ T cells (Tc17) appear to play a role in a range of conditions, such as autoimmunity and cancer. Thus far, Tc17 cells have been only marginally studied, resulting in a paucity of data on their biology and function. We demonstrate that Tc17 and Th17 cells share similar developmental characteristics, including the previously unknown promoting effect of IL-21 on Tc17 cell differentiation and IL-23-dependent expression of IL-22. Both STAT1 and STAT4 are required for optimal development of Tc17 cells and maximal secretion of cytokines. Tc17 cells are cytotoxic, and they can be either pathogenic or nonpathogenic upon adoptive transfer in the model of autoimmune diabetes. Tc17 cells treated with TGF-β1 plus IL-6 are not diabetogenic, whereas IL-23-treated cells potently induce the disease. IL-17A and IL-17F are necessary but not sufficient for diabetes induction by Tc17 cells. Tc17 cells treated with TGF-β1 plus IL-6 or IL-23 likely differ in pathogenicity due to their disparate capacity to attract other immune cells and initiate inflammation.
Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841
Kim, George P., Sargent, Daniel J. , Mahoney, Michelle R., Rowland, Kendrith M. , Mitchell, Edith P. , Mathews, Abraham P., Fitch, Tom R., Goldberg, Richard M. , Pitot, Henry C., Philip, Philip A. , Alberts, Steven R. , Sargent, Daniel J

Mayo Clinic

Journal of Clinical Oncology | April 21, 2009 | Volume: 27 | Issue: 17 | Pages: 2848-2854

10.1200/jco.2008.20.4552 | PMID 19380443 Get It

Purpose The primary goal of this multicenter phase III trial was to determine whether overall survival (OS) of fluorouracil (FU) -refractory patients was noninferior when treated with second-line infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4; arm B) versus irinotecan (arm A). Cross-over to the other treatment on disease progression was mandated. Patients and Methods Patients who experienced treatment failure with one prior FU-based therapy and had not received prior irinotecan or oxaliplatin, either for metastatic disease or within 6 months of adjuvant FU therapy, were randomly assigned to arm A (irinotecan 350 or 300 mg/m2 every 3 weeks) or arm B (FOLFOX4). Results A total of 491 patients were randomly assigned (arm A, n = 245; arm B, n = 246); 288 (59%) had experienced treatment failure with FU for metastatic colorectal cancer. Two hundred twenty-seven patients (46%) received protocol-mandated third-line therapy (arm A, 43%; arm B, 57%). Median survival was 13.8 months (95% CI, 12.2 to 15.0 months) for initial treatment with FOLFOX4 and 14.3 months (95% CI, 12.0 to 15.9 months) for irinotecan (P = .38; hazard ratio = 0.92; 95% CI, 0.8 to 1.1). Response rates (RR; 28% v 15.5%; P = .0009) and time to progression (TTP; 6.2 v 4.4 months; P = .0009) were significantly superior with FOLFOX4. In the nonrandom subset of patients who crossed over, RR and TTP improvements with FOLFOX4 continued into third-line treatment. Irinotecan therapy was associated with more grade 3 nausea, vomiting, diarrhea, and febrile neutropenia; FOLFOX4 was associated with more neutropenia and paresthesias. Conclusion In patients who experienced treatment failure with front-line FU therapy, OS does not significantly differ whether second-line therapy begins with irinotecan or FOLFOX4. FOLFOX4 produces higher RR and longer TTP. Both arms had notable OS in patients who experienced treatment failure with first-line FU therapy.
Usual Interstitial Pneumonia and Non-Specific Interstitial Pneumonia: Serial Thin-Section CT Findings Correlated with Pulmonary Function
Jeong, Yeon Joo , Lee, Kyung Soo , Müller, Néstor L. , Chung, Man Pyo , Chung, Myung Jin , Han, Joungho , Colby, Thomas V. , Kim, Seonwoo

Mayo Clinic

Korean Journal of Radiology | April 20, 2009 | Volume: 6 | Issue: 3 | Pages: 143

10.3348/kjr.2005.6.3.143 | PMID 16145289 Get It

Plasma Carboxy-Terminal Provasopressin (Copeptin): A Novel Marker of Insulin Resistance and Metabolic Syndrome
Saleem, Umer, Khaleghi, Mahyar, Morgenthaler, Nils G., Bergmann, Andreas , Struck, Joachim , Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | April 14, 2009 | Volume: 94 | Issue: 7 | Pages: 2558-2564

10.1210/jc.2008-2278 | PMID 19366852 Get It

Context: Stress-mediated hypothalamic-pituitary-adrenal axis activation, regulated by arginine vasopressin (AVP), may have a role in the pathophysiology of metabolic syndrome (MetSyn). Objective: The objective of the study was to investigate whether plasma C-terminal provasopressin fragment (copeptin), a surrogate for circulating AVP, was associated with measures of insulin resistance and presence of MetSyn. Design, Setting, and Participants: This was a multicenter, community-based study, investigating novel biomarkers for vascular disease. Participants included 1293 African-Americans (AA) (64 ± 9 yr) and 1197 non-Hispanic whites (NHW) (59 ± 10 yr) belonging to hypertensive sibships. Main Outcome Measures: Plasma copeptin levels were measured by an immunoluminometric assay. MetSyn was defined per Adult Treatment Panel III criteria. Generalized estimating equations were used to assess whether plasma copeptin was associated with measures of insulin resistance and MetSyn. Results: The prevalence of MetSyn was 50% in AA and 49% in NHW. In each group, after adjustment for age and sex, plasma copeptin levels significantly correlated with body mass index, fasting plasma glucose and insulin, homeostasis model assessment of insulin resistance, triglycerides, and (inversely) high-density lipoprotein cholesterol (P &lt; 0.05 for each variable). In multivariable logistic regression models that adjusted for age, sex, smoking, statin use, serum creatinine, education, physical activity, and diuretic use, plasma copeptin levels in the highest quartile were associated with an increased odds ratio of having MetSyn compared with bottom quartile: odds ratio (95% confidence interval) in AA, 2.07 (1.45–2.95); in NHW, 1.74 (1.21–2.5). Conclusions: Our findings indicate a novel cross-sectional association between plasma copeptin and measures of insulin resistance and MetSyn.